CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to "emerging technology trends, including opportunities across the AI value chain", announced on 18 August 2026. All changes will be implemented after the market close on 11 September 2026 (Friday) and take effect on 14 September 2026 (Monday).

The HKEX Tech 100 Index is designed to measure the performance of 100 of the largest Hong Kong-listed companies with high exposure to key tech themes, that are eligible for Southbound Stock Connect, addressing growing market demand for diversified exposure to the technology sector. The benchmark focuses on the nature of core business, revenue distribution and industry classification for constituent evaluation, and covers both leading and emerging companies, spanning six themes, including artificial intelligence, biotech & pharmaceutical, electric vehicles & smart driving, information technology, internet and robotics.

Recommended for you